Federal Circuit Affirms PTAB Invalidity in Shockwave v. CSI Catheter Patent Battle

Case Overview

The Parties

The Patent at Issue

US Patent No. 8,956,371 B2 (Application No. US12/482,995) covers innovations in the Shockwave balloon catheter system — specifically technology enabling intravascular lithotripsy for calcified lesion treatment. The disputed claims (1–17) govern key structural and functional aspects of the catheter design.

Legal Representation

Plaintiff (Shockwave): Gardella Grace PA and Irell & Manella LLP; attorneys Cook Alciati, David C. McPhie, Michael Richard Fleming, and Stephen Payne

Defendant (CSI): Latham & Watkins, LLP; attorneys Gabriel K. Bell, Hannah Fan, Jacob Vannette, and Michael A. Morin

Litigation Timeline & Procedural History

The dispute reached the Federal Circuit following PTAB proceedings, with Shockwave filing its appeal on May 9, 2023. The case closed July 14, 2025, spanning 797 days — a timeline consistent with contested Federal Circuit patent appeals involving cross-appeals and complex technical records.

The procedural posture involved both a direct appeal by Shockwave (challenging the Board’s cancellation of claims 1–4 and 6–17) and a cross-appeal by CSI (challenging the Board’s determination to uphold claim 5). This dual-appeal structure — where each party challenges discrete portions of a PTAB final written decision — is increasingly common in IPR proceedings involving patents with numerous claims.

The PTAB served as the primary fact-finding tribunal. The Federal Circuit’s role was appellate review of the Board’s patentability conclusions, applying deferential standards to factual findings while reviewing legal conclusions de novo.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued an affirmed-in-part and reversed-in-part decision:

• • Claims 1–4 and 6–17: AFFIRMED — The Board’s cancellation of these claims was upheld. Shockwave’s arguments challenging the invalidity determinations were found unpersuasive by the appellate panel.
• • Claim 5: REVERSED — The Board’s determination sustaining claim 5 was reversed on CSI’s cross-appeal, meaning claim 5 was also rendered invalid/canceled.

No damages were applicable — this was a patentability proceeding, not a district court infringement trial. The net result leaves US8956371B2 fully or substantially stripped of enforceable claims.

Verdict Cause Analysis

The verdict cause is classified as patentability — invalidity/cancellation action, consistent with IPR proceedings where a petitioner challenges patent claims on prior art grounds (anticipation or obviousness under 35 U.S.C. §§ 102–103).

The Federal Circuit’s summary treatment of Shockwave’s arguments — characterizing them collectively as “unpersuasive” without detailed rebuttal — suggests the panel found no reversible error in the Board’s underlying factual analysis. In Federal Circuit jurisprudence, this language typically signals that the Board’s prior art findings were supported by substantial evidence, the legal standard governing IPR appeals.

On the cross-appeal regarding claim 5, the reversal indicates the Board had made a legal or factual error in distinguishing that claim from the prior art. This is a meaningful development: CSI succeeded not only in defending its IPR victory on the bulk of the patent, but also in expanding the cancellation to a claim the Board had initially spared.

Legal Significance

• • Scope of Appellate Deference: The Federal Circuit’s consistent affirmance reinforces the difficulty of overturning PTAB invalidity determinations on appeal. Substantial evidence review heavily favors the Board’s fact-finding, making robust record-building at the IPR stage essential.
• • Cross-Appeal Strategy: CSI’s successful cross-appeal on claim 5 demonstrates the value of preserving and pursuing cross-appeals even when a petitioner achieves substantial success at PTAB. Leaving a single upheld claim unchallenged can preserve a patentee’s litigation leverage.
• • Independent Claim Vulnerability: With claims 1–4 and 6–17 canceled and claim 5 reversed on cross-appeal, the patent’s full claim scope appears invalidated — underscoring how IPR can systemically dismantle a patent’s enforceability.

Strategic Takeaways

For Patent Holders:

• • Invest in prosecution strategies that build claim differentiation and thorough specification support, reducing IPR vulnerability
• • Anticipate cross-appeals when PTAB issues split decisions — a partially favorable Board decision may invite further appellate exposure

For Accused Infringers:

• • Comprehensive IPR petitions targeting all commercially significant claims — paired with a cross-appeal strategy — can achieve complete neutralization of an asserted patent
• • Latham & Watkins’ dual success (affirming cancellation on direct appeal, reversing on cross-appeal) reflects sophisticated post-grant litigation coordination

For R&D Teams:

• • Freedom-to-operate (FTO) analyses should account for post-IPR claim landscapes; canceled claims eliminate infringement risk prospectively
• • Monitor competitor patent portfolios for IPR petition opportunities when design-around costs are high

Industry & Competitive Implications

The cancellation of Shockwave’s US8956371B2 claims has tangible competitive consequences in the intravascular lithotripsy and calcified lesion treatment device market. Shockwave Medical has built a formidable IP fortress around its IVL platform, and adverse IPR outcomes threaten the exclusivity underpinning its market position.

For CSI and competitors in the atherectomy and catheter-based intervention space, the ruling potentially clears design and commercialization pathways previously constrained by Shockwave’s patent portfolio. However, Shockwave’s broader IP estate likely encompasses additional patents covering IVL system components — making freedom-to-operate analysis across the full portfolio essential before drawing competitive conclusions.

The case also reflects a broader medtech trend: aggressive post-grant challenge strategies have become standard competitive tools in high-value device categories. Companies with significant R&D investments in overlapping therapeutic areas routinely employ IPR as both a defensive and offensive instrument, particularly where litigation costs in district court would be prohibitive.

For licensing professionals, the outcome may affect the leverage dynamics of any ongoing or future licensing negotiations involving Shockwave’s IVL patent portfolio — at minimum creating uncertainty that complicates royalty valuation.